title: Sorafenib-Induced Grade Four Hepatotoxicity in a Patient with Recurrent Gastrointestinal Stromal Tumor (GIST): A Case Report and Review of Literature.
abstract: Gastrointestinal stromal tumor is a rare mesenchymal tumor. Sorafenib is an effective medication in these tumors based on two phase II clinical trials and a retrospective analysis. We report a rare case of a 57-year-old male with acute hepatotoxicity from sorafenib. He was treated conservatively with IV fluids and prednisolone. Liver function tests improved over 2 months. We conclude that sorafenib could cause life-threatening hepatotoxicity and patients taking sorafenib need to be closely monitored.
authors.affiliation: Division of Hematology and Oncology, University of New Mexico Cancer Center, Albuquerque, NM.
authors.forename: Waheed
authors.initials: W
authors.lastname: Murad
authors.affiliation: Division of Hematology and Oncology, University of New Mexico Cancer Center, Albuquerque, NM.
authors.forename: Ian
authors.initials: I
authors.lastname: Rabinowitz
authors.affiliation: Division of Hematology and Oncology, University of New Mexico Cancer Center, Albuquerque, NM.
authors.forename: Fa-Chyi
authors.initials: FC
authors.lastname: Lee